Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sankyo Company has initiated a phase IIb trial to evaluate the safety and efficacy of its drug candidate CS-917 for the treatment of patients with type 2 diabetes.
Subscribe to our email newsletter
Patients in the study will receive CS-917, placebo, or an active comparator for a period of three months.
CS-917 is a first-in-class, orally active, inhibitor of FBPase, an enzyme that regulates production of glucose in the liver. The drug, which Sankyo licensed from biopharmaceutical company Metabasis, has shown promise as a treatment for diabetes in preclinical and early clinical studies.
In two previously completed phase IIa clinical trials involving a total of 185 patients with type 2 diabetes, treatment with CS-917 resulted in clinically and statistically significant reductions in blood sugar levels.
If successfully developed, CS-917 is expected to be used alone or in combination with certain other diabetes therapies that target the removal of glucose from the blood.